Medicine and Dentistry
Aflibercept
13%
Age Related Macular Degeneration
18%
Agents Acting on the Eye
14%
Best Corrected Visual Acuity
20%
Bevacizumab
30%
Branch Retinal Vein Occlusion
16%
Cataract
16%
Cataract Surgery
44%
Central Retinal Vein Occlusion
40%
Clinical Feature
11%
Clinical Trial
18%
Diabetic Macular Edema
31%
Diabetic Retinopathy
26%
Drug Therapy
11%
Endophthalmitis
59%
Fluorescein
10%
Glaucoma
16%
Hemiretinal Vein Occlusion
27%
Implant
14%
Intraocular Lens
11%
Intraocular Pressure
25%
Intravitreal Administration
28%
Laser Coagulation
23%
Macular Edema
45%
Medical Record
8%
Neoplasm
9%
Ophthalmology
27%
Optical Coherence Tomography
31%
Pars Plana Vitrectomy
32%
Phacoemulsification
10%
Proliferative Diabetic Retinopathy
24%
Randomized Clinical Trial
21%
Ranibizumab
15%
Retina Vein Occlusion
31%
Retinal Detachment
30%
Retinoblastoma
8%
Silicone Oil
12%
Spectral Domain Optical Coherence Tomography
8%
Surgeon
9%
Trabeculectomy
9%
Triamcinolone
14%
Triamcinolone Acetonide
17%
Vasculotropin
32%
Vision
7%
Visual Acuity
100%
Visual Impairment
13%
Vitrectomy
11%
Vitreoretinal Surgery
10%
Vitreous
8%
Vitreous Hemorrhage
7%
Keyphrases
Acute Onset
9%
Aflibercept
18%
Age-related Macular Degeneration
30%
American Academy of Ophthalmology
13%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
21%
Anti-vascular Endothelial Growth Factor Therapy
15%
Avastin
9%
Best-corrected Visual Acuity
20%
Bevacizumab
25%
Branch Retinal Vein Occlusion
15%
Cataract
10%
Cataract Surgery
41%
Central Subfield Thickness
16%
Central Vein Occlusion
11%
Clinical Features
12%
Confidence Interval
10%
Corticosteroids
18%
Diabetic Macular Edema
34%
Diabetic Retinopathy
13%
Early Treatment Diabetic Retinopathy Study
12%
Endophthalmitis
51%
Glaucoma
9%
Intraocular Pressure
18%
Intravitreal
14%
Intravitreal Bevacizumab
27%
Intravitreal Injection
28%
Intravitreal Ranibizumab
12%
Intravitreal Triamcinolone Acetonide Injection
8%
Macular Edema
42%
Ophthalmology
8%
Optical Coherence Tomography
24%
Pars Plana Vitrectomy
35%
Proliferative Diabetic Retinopathy
18%
Randomized Clinical Trial
14%
Ranibizumab
9%
Recurrent Retinal Detachment
15%
Retina
14%
Retinal Detachment
13%
Retinal Thickness
12%
Retinal Vein Occlusion
73%
Retinoblastoma
10%
Rhegmatogenous Retinal Detachment
11%
Triamcinolone Acetonide
16%
United States
12%
Vision Loss
9%
Visual Acuity
85%
Visual Acuity Outcome
25%
Visual Impairment
9%
Visual Outcome
16%
Vitreoretinal Surgery
12%